FRCS

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial

Share:

Authors: Bonaca MP et al. https://pubmed.ncbi.nlm.nih.gov/29133605 #Secondary Prevention in Peripheral Vascular Disease A. Period of study: The parent FOURIER trial recruited participants from February 2013 to June 2015. Patients were followed for a median of 2.2 years. It was conducted at 1,242 sites across 49 countries. B. Publication date & Journal: Journal: CirculationOnline publication: 13th […]

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial Read More »

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

Share:

Authors: C Baigent at al, Cholesterol Treatment Trialists’ (CTT) Collaboration 1; Lancet 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5 https://www.thelancet.com/article/S0140-6736(10)61350-5/fulltext #Secondary Prevention in Peripheral Vascular Disease A. Period of study (start – end): Included trials were published from 1994-2009 B. Publication date & Journal: November, 2010 The Lancet Journal Impact Factor (2025): 109.0 C. TL;DR (Bottom Line)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Read More »

Scroll to Top